Sarcoid-like Reaction in Cases Treated by Checkpoint Inhibitors

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2021 Feb 18

PMID 33598792

Citations 5

Authors

Semra Paydas

Affiliations

Soon will be listed here.

Abstract

Sarcoidosis is a multisystem granulomatous disorder characterized by helper T cell inflammation. Sarcoid-like reaction (SLR) is a well-defined entity and may be related with several malignant disorders and/or their therapies. SLR has been reported more than 20 years ago and in recent years in cases treated by checkpoint inhibitors (CPIs). Better outcome has been reported in cases developing granulomatous reaction and/or SLRs during CPI treatments. However, these lesions clinically may be thought as disease progression and may cause to stop treatment or alterations. These therapeutic manipulations may be harmful for the patients. Clinicians should be aware of SLRs in cases treated by CPIs and tissues must be sampled and reviewed by an experienced pathologist to avoid misdiagnosis and also unnecessary CPI treatment cessations.Significance StatementClinicians should be aware of sarcoid-like reactions in cases treated by checkpoint inhibitors and tissues must be sampled and reviewed by an experienced pathologist to avoid misdiagnosis and CPI treatment stops.

Citing Articles

Sarcoidosis and Cancer: The Role of the Granulomatous Reaction as a Double-Edged Sword.

Di Francesco A, Pasciuto G, Verrecchia E, Sicignano L, Gerardino L, Massaro M J Clin Med. 2024; 13(17).

PMID: 39274446 PMC: 11396756. DOI: 10.3390/jcm13175232.

Sarcoid-like reaction induced by neoadjuvant immunotherapy in Stage III non-small cell lung cancer.

Machado L, Fonseca E, Oliveira Junior G, Schvartsman G, Chate R Einstein (Sao Paulo). 2024; 22:eAI0810.

PMID: 38567916 PMC: 11081020. DOI: 10.31744/einstein_journal/2024AI0810.

Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.

de Boer J, Pennings E, Kleinjan A, van Doesum J, Spanjaart A, Mutsaers P Blood Adv. 2023; 7(21):6710-6716.

PMID: 37639324 PMC: 10641469. DOI: 10.1182/bloodadvances.2023010665.

Immunotherapy-induced exclusively cutaneous sarcoid-like reaction.

Mazumder A, Mehrmal S, Chaudhry S BMJ Case Rep. 2023; 16(7).

PMID: 37463781 PMC: 10357716. DOI: 10.1136/bcr-2022-252766.

The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.

Pantarotto M, Barata R, Coelho R, Carvalheiro C, Rolim I, Garrido P Cureus. 2022; 14(7):e26729.

PMID: 35967142 PMC: 9364060. DOI: 10.7759/cureus.26729.

References

Hunt B, Vallieres E, Buduhan G, Aye R, Louie B . Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg. 2009; 197(5):629-32. DOI: 10.1016/j.amjsurg.2009.01.004. View

Cohen P, Kurzrock R . Sarcoidosis and malignancy. Clin Dermatol. 2007; 25(3):326-33. DOI: 10.1016/j.clindermatol.2007.03.010. View

Paydas S, Yavuz S, Disel U, Zeren H, Hasturk S, Hanta I . Granulomatous reaction after chemotherapy for Hodgkin's disease. Leuk Res. 2002; 26(10):967-70. DOI: 10.1016/s0145-2126(02)00070-x. View

Suditu N, Negru D . Bacillus Calmette-Guérin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: A case report and literature review. Mol Clin Oncol. 2014; 3(1):249-251. PMC: 4251198. DOI: 10.3892/mco.2014.422. View

Clerigo V, Castro A, Mourato T, Gomes C . A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer. Acta Med Port. 2019; 32(4):316-320. DOI: 10.20344/amp.10250. View

Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L . Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2008; 218(1):69-70. DOI: 10.1159/000161122. View

Tirumani S, Ramaiya N, Keraliya A, Bailey N, Ott P, Hodi F . Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015; 3(10):1185-92. PMC: 4596761. DOI: 10.1158/2326-6066.CIR-15-0102. View

Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S . Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2010; 66(2):144-50. DOI: 10.1136/thx.2010.140319. View

ten Berge B, Paats M, Bergen I, van den Blink B, Hoogsteden H, Lambrecht B . Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford). 2011; 51(1):37-46. DOI: 10.1093/rheumatology/ker316. View

10.

Naccache J, Antoine M, Wislez M, Fleury-Feith J, Oksenhendler E, Mayaud C . Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Am J Respir Crit Care Med. 1999; 159(6):2009-13. DOI: 10.1164/ajrccm.159.6.9807152. View

11.

Ishida M, Hodohara K, Furuya A, Okuno H, Yoshii M, Horinouchi A . Sarcoidal granulomas in the mediastinal lymph nodes after treatment for marginal zone lymphoma of the esophagus: report of a case with review of the concept of the sarcoidosis-lymphoma syndrome. Int J Clin Exp Pathol. 2014; 7(7):4428-32. PMC: 4129064. View

12.

Acosta-Rodriguez E, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A . Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007; 8(6):639-46. DOI: 10.1038/ni1467. View

13.

Ramesh R, Kozhaya L, McKevitt K, Djuretic I, Carlson T, Quintero M . Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014; 211(1):89-104. PMC: 3892977. DOI: 10.1084/jem.20130301. View

14.

Ramstein J, Broos C, Simpson L, Ansel K, Sun S, Ho M . IFN-γ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells. Am J Respir Crit Care Med. 2015; 193(11):1281-91. PMC: 4910899. DOI: 10.1164/rccm.201507-1499OC. View

15.

Lomax A, McGuire H, McNeil C, Choi C, Hersey P, Karikios D . Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis. Int J Rheum Dis. 2017; 20(9):1277-1285. DOI: 10.1111/1756-185X.13076. View

16.

Saidha S, Sotirchos E, Eckstein C . Etiology of sarcoidosis: does infection play a role?. Yale J Biol Med. 2012; 85(1):133-41. PMC: 3313528. View

17.

Al-Dliw M, Megri M, Shahoub I, Sahay G, Limjoco T, Shweihat Y . Pembrolizumab reactivates pulmonary granulomatosis. Respir Med Case Rep. 2017; 22:126-129. PMC: 5540828. DOI: 10.1016/j.rmcr.2017.07.010. View

18.

Cotliar J, Querfeld C, Boswell W, Raja N, Raz D, Chen R . Pembrolizumab-associated sarcoidosis. JAAD Case Rep. 2016; 2(4):290-3. PMC: 4969257. DOI: 10.1016/j.jdcr.2016.06.004. View

19.

Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M, Rodriguez-Peralto J, Ortiz-Romero P . Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum. JAMA Dermatol. 2017; 153(7):721-722. DOI: 10.1001/jamadermatol.2017.0581. View

20.

Lopez A, Khanna T, Antonov N, Audrey-Bayan C, Geskin L . A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018; 57(6):664-669. DOI: 10.1111/ijd.13984. View